Mapatumumab

马帕木单抗

Report date: 2022/07/19 20:00:45

Base Information

Drug NameMapatumumab
Drug Alias Name马帕木单抗mapatumumabum玛帕妥木单抗TRAIL-R1 monoclonal antibodyTRAIL-R1 +[9] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionTumor necrosis factor receptor superfamily member 10A agonistsApoptosis inducers
TargetsTumor necrosis factor receptor superfamily member 10A
Therapy Area/IndicationsUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell LungMultiple Myeloma +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited StatesUkraine +[11] 
CombinationsNo
Global Highest StatusPending (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesCambridge Antibody Technology
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesUniversity Medical Center GroningenGlaxosmithkline PlcHuman Genome Sciences Inc
Active IndicationsN/A
Inactive IndicationsUterine Cervical NeoplasmsCarcinoma, Non-Small-Cell LungMultiple Myeloma +[5] 

Other Information

ATC CodeN/A
Related LinksWikipediaKEGG